Renin inhibitors as novel treatments for cardiovascular disease

Bibliography

• HACKENTHAL E, PAUL M, GANTEN D et al.: Morphology, physiology, and molecular biology of renin secretion. Physiol Rev (1990) 70(4):1067–1116.
   PubMed Web of Science ®Google Scholar
• JAMES MN, SIELECKI AR: Stereochemical analysis of peptide bond hydrolysis catalyzed by the aspartic proteinase penicillopepsin. Biochemistry (1985) 24(14):3701–3713.
   PubMed Web of Science ®Google Scholar
• DELLIPIZZI AM, HILCHEY SD, BELL-QUILLEY CP: Natriuretic action of angiotensin (1-7). Br. J. Pharmacol (1994) 111(1):1–3.
   PubMed Web of Science ®Google Scholar
• SWANSON GN, HANESWORTH JM, SARDINIA MF et al.: Discovery of a distinct binding site for angiotensin 11 (3-8), a putative angiotensin IV receptor. Regal Pept. (1992) 40(3):409–419.
   PubMedGoogle Scholar
• MACGREGOR GA, MARKANDU ND, ROULSTON JE et al.: Maintenance of blood pressure by the renin-angiotensin system in normal man. Nature (1981) 291(5813):329–331.
   PubMed Web of Science ®Google Scholar
• SKEGGS LT, KAHN JR, LENTZ KE et al.: Preparation, purification and amino acid sequence of a polypeptide renin substrate. J. Exp. Med. (1957) 106:439–453.
   PubMed Web of Science ®Google Scholar
• ••The first study to recognise that inhibitionof renin represented the optimum means of inhibiting the RAS.
   Google Scholar
• WOOD JM, STANTON JL, HOFBAUER KG: Inhibitors of renin as potential therapeutic agents. I Enzyme Inhib. (1987) 1(3):169–185.
   PubMedGoogle Scholar
• KARLBERG BE: Cough and inhibition of the renin-angiotensin system. Hypertens. Sapp]. (1993) 11(3):549–552.
   Google Scholar
• HOLLENBERG NK, FISHER ND, PRICE DA: Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension (1998) 32(3):387–392.
   PubMed Web of Science ®Google Scholar
• FISHER ND, HOLLENBERG NK: Is there a future for renin inhibitors? Expert Opin. Investig. Drugs (2001) 10(3):417–426.
   Google Scholar
• LUFT FC, MERVAALA E, MULLER DN et al.: Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension (1999)33(1 Pt 2):212–218.
   Google Scholar
• ••This paper describes the development of thedouble transgenic rat model of RAS-induced end organ damage.
   Google Scholar
• LARAGH JH, CASE DB, WALLACE JM et al.: Blockade of renin or angiotensin for understanding human hypertension: a comparison of propranolol, saralasin and converting enzyme blockade. Fed Proc. (1977) 36(5):1781–1787.
   PubMedGoogle Scholar
• OGIHARA T, MARUYAMA A, HATA T et al: Hormonal responses to long-term converting enzyme inhibition in hypertensive patients. Clin. Pharmacol Ther. (1981) 30(3):328–335.
   PubMed Web of Science ®Google Scholar
• VAN DEN MEIRACKER AH, MAN IN 'T VELD AJ, ADMIRAAL PJ et al: Partial escape of angiotensin-converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? Hypertens. (1992) 10(8):803–812.
   Google Scholar
• MERVAALA E, MULLER DN, SCHMIDT F et al.: Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension (2000) 35(2):587–594.
   PubMed Web of Science ®Google Scholar
• RAMAN VK, LEE YA, LINDPAINTNER K: The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. Am. Cardiol. (1995) 76(13):18D-23D.
   Google Scholar
• •Describes a link between RAS hyperactivation and cardiac hypertrophy in humans.
   Google Scholar
• MEZZANO SA, RUIZ-ORTEGA M, EGIDO J: Angiotensin II and renal fibrosis. Hypertension (2001) 38(3 Pt 2):635–638.
   Google Scholar
• •Indicates the role of Ang II-induced renal tissue damage independent of hypertensive effects in humans.
   Google Scholar
• LEE AF, MACFADYEN RJ, STRUTHERS AD: Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur. J. Heart Fail. (1999) 1(4):401–406.
   PubMed Web of Science ®Google Scholar
• WOLNY A, CLOZEL JP, REIN J et al: Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ. Res. (1997) 80(2):219–227.
   PubMed Web of Science ®Google Scholar
• PRICE DA, PORTER LE, GORDON M et al: The paradox of the low-renin state in diabetic nephropathy. j Am. Soc. Nephrol (1999) 10(11):2382–2391.
   PubMed Web of Science ®Google Scholar
• YUSUF S, SLEIGHT P, POGUE Jet al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl. J. Med. (2000) 342(3):145–153.
   Google Scholar
• CHATURVEDI N, SJOLIE AK, STEPHENSON JM et al.: Effect of lisinopril on progression of retinopathy in normotensive people with Type 1 diabetes. The EUCLID study group. EURODIAB controlled trial of lisinopril in insulin-dependent diabetes mellitus. Lancet (1998) 351(9095):28–31.
   Google Scholar
• TAHMASEBI M, PUDDEFOOT Jr, INWANG ER et al: The tissue renin-angiotensin system in human pancreas. J. Endocrinol (1999) 161(2):317–322.
   PubMed Web of Science ®Google Scholar
• WEBB RL, NAVARRETE AE, DAVIS S: Effects of valsartan and hydrochlorothiazide alone and in combination on blood pressure and heart rate in conscious-telemetered spontaneously hypertensive rats (SHR). Am. J. Hypertens. (1998)11(1 Pt 1):59–65.
   Google Scholar
• WAEBER B, ASCHWANDEN R, SADECKY L et al.: Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. J. Hypertens. (2001) 19(11):2097–2104.
   PubMed Web of Science ®Google Scholar
• SCHMIDT A, ADAM SA, KOLLOCH R et al.: Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension. Blood Press. (2001) 10(4):230–237.
   PubMed Web of Science ®Google Scholar
• FOGARI R, ZOPPI A, TETTAMANTI F et al.: Fixed combination of benazepril and very low dose hydrochlorothiazide in the treatment of mild to moderate essential hypertension: evaluation by 24-hour non-invasive ambulatory blood pressure monitoring. Int. I Clin. PharmacoL Ther. (1994) 32(11):606–611.
   PubMed Web of Science ®Google Scholar
• NEUTEL JM, LUTHER RR, BOGER RS et al.: Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat. Am. Heart J. (1991)122(4 Pt 1):1094–1100.
   Google Scholar
• WEBB RL, NAVARRETE AE, DAVIS S et aL: Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats. Hypertens. (1998) 16(6):843–852.
   Web of Science ®Google Scholar
• MICHEL JB, GALEN FX, GUETTIER C et al.: Immunological approach to blockade of the renin-substrate reaction. J. Hypertens. SuppL (1989) 7(2):563–570.
   Google Scholar
• CUMIN F, EVIN G, FEHRENTZ JA et al.: Inhibition of human renin by synthetic peptides derived from its prosegment. j. Biol. Chem. (1985) 260(16):9154–9157.41. KLEINBLOESEM CH, WEBER C, FAHRNER E et al.: Hemodynamics, biochemical effects, and pharmacokinetics of51. the renin inhibitor remikiren in healthy human subjects. Clin. Pharmacol Ther:(1993) 53(5):585–592.
   Google Scholar
• HABER E: Peptide inhibitors of renin in cardiovascular studies. Fed. Proc. (1983) 42(15):3155–3161.
   PubMedGoogle Scholar
• SZELKE M, LECKIE B, HALLETT A et al: Potent new inhibitors of human renin. Nature (1982) 299(5883):555–557.
   PubMed Web of Science ®Google Scholar
• BOGER J, LOHR NS, ULM EH et al.: Novel renin inhibitors containing the amino acid statine. Nature (1983) 303 (5912) :81–84 .
   PubMed Web of Science ®Google Scholar
• WEBB DJ, MANHEM PJ, BALL SG et al: A study of the renin inhibitor H142 in man. Hypertens. (1985) 3(6):653–658.
   Web of Science ®Google Scholar
• WOOD JM, GULATI N, FORGIARINI P et al.: Effects of a specific and long-acting renin inhibitor in the marmoset. Hypertension (1985) 7(5):797–803.
   PubMed Web of Science ®Google Scholar
• •The first renin inhibitor to demonstrate effectiveness in lowering blood pressure in primates.
   Google Scholar
• KLEINERT HD, MARTIN D, CHEKAL MA et al.: Effects of the renin inhibitor A-64662 in monkeys and rats with varying baseline plasma renin activity. Hypertension (1988) 11(6 Pt 2):613–619.
   Google Scholar
• WOOD JM, CRISCIONE L, DE GASPARO M et al.: CGP 38 560: orally active, low-molecular-weight renin inhibitor with high potency and specificity. I Cardiovasc. Pharmacol (1989) 14(2):221–226.
   Google Scholar
• FISCHLI W, CLOZEL JP, EL AMRANI K et al.: Ro 42–5892 is a potent orally active renin inhibitor in primates. Hypertension (1991) 18(1):22–31.
   Google Scholar
• DE GASPARO M, CUMIN F, NUSSBERGER J et al: Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. Br. J. Clin. Phannacol (1989) 27(5):587–596.
   PubMed Web of Science ®Google Scholar
• BOYD SA, FUNG AK, BAKER WR et al.:C-terminal modifications of non-peptide renin inhibitors: improved oral bioavailability via modification of physicochemical properties.j Med. Chem. (1992) 35(10):1735–1746.
   Google Scholar
• ZIEGLER K, KOLAC C, SCHULZE S et al.: Hepatobiliary elimination of certain peptide-mimicking drugs: linear hydrophobic and hydrophilic renin-inhibitors and hydrophobic cyclopeptides. Hepatol (1996) 24\(Supp1.1):47–52.
   Google Scholar
• ROSENBERG SH, SPINA KP, CONDON SL et al: Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2.5)-2-benzy1-3- [[(1-methylpiperazin-4-y0sulfonyllpropiony11-3-thiazol 4 yl L alanine amide of (2S,3R,45)-2-amino-1-cyclohexy1-3,4-dihydroxy-6-methylheptane (A-72517). J. Med. Chem. (1993) 36(4):460–467.
   Google Scholar
• KLEINERT HD, ROSENBERG SH, BAKERWR et aL: Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. Science (1992) 257(5078):1940–1943.
   PubMed Web of Science ®Google Scholar
• MENARD J, BOGER RS, MOYSE DM et al.: Dose-dependent effects of the renin inhibitor zankiren HC1 after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation (1995) 91(2):330–338.
   PubMed Web of Science ®Google Scholar
• WOOD JM, CUMIN F, MAIBAUM J: Pharmacology of renin inhibitors and their application to the treatment of hypertension. Pharmacol Ther. (1994) 61(3):325–344.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of the development of peptide-like renin inhibitors.
   Google Scholar
• VERBURG KM, KLEINERT HD, KADAM JR et al.: Effects of chronic infusion of renin inhibitor A-64662 in sodium-depleted monkeys. Hypertension (1989) 13(3):262–272.
   PubMed Web of Science ®Google Scholar
• WOOD JM, JOBBER RA, BAUM HP et al.: Biochemical effects of prolonged renin inhibition in marmosets.' Hypertens. (1989) 7(8):615–618. CAMENZIND E, NUSSBERGER J, JUILLERAT L et al.: Effect of the renin response during renin inhibition: oral Ro 42–5892 in normal humans. .1. Cardiovasc. Pharmacol (1991) 18(3):299–307.
   Google Scholar
• HOFBAUER KG, WOOD NI, GULATI Net al: Increased plasma renin during renin inhibition. Studies with a novel immunoassay. Hypertension (1985) 7(3 Pt 2):I61–165.
   Google Scholar
• BOGER RS, GLASSMAN H, THYS R et al.: Absorption and blood pressure response to the new orally active renin inhibitor, A-72517 in hypertensive patients. Am. J. Hypertens. (1993) 6:103A.
   PubMedGoogle Scholar
• TOFFELMIRE EB, SLATER K, CORVOL P et al.: Response of plasma prorenin and active renin to chronic and acute alterations of renin secretion in normal humans. Studies using a direct immunoradiometric assay. J. Clin. Invest. (1989) 83(2):679–687.
   PubMed Web of Science ®Google Scholar
• JEUNEMAITRE X, MENARD J, NUSSBERGER J et al.: Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients. Am. Hypertens. (1989)2(11 Pt 1):819–827.
   Google Scholar
• DERKX FH, VAN DEN MEIRACKER AH, FISCHLI W et al.: Non-parallel effects of renin inhibitor treatment on plasma renin activity and angiotensins I and II in hypertensive subjects. An assay-related artifact. Am. J. Hypertens. (1991) 4(7 Pt 1):602–609.
   Google Scholar
• CLOZEL JP, FISCHLI W: Discovery of remikiren as the first orally active renin inhibitor. Arzneimittelforschung (1993) 43(24260–262.
   Web of Science ®Google Scholar
• WOOD JM, JOBBER RA, BAUM HP et al.: Comparison of chronic inhibition of renin and converting enzyme in the marmoset. Clin. Exp. Hypertens. A (1987) 9(2-3):337–343.
   PubMed Web of Science ®Google Scholar
• OLDHAM AA, ARNSTEIN MJ, MAJOR JS et al.: hi vivo comparison of the renin inhibitor H77 with the angiotensin-converting enzyme inhibitor captopril. .1. Cardiovasc. Pharmacol (1984) 6(4):672–677.
   Google Scholar
• WOOD JM, MAH SC, SCHNELL C: Comparison of the acute hypotensive effects of renin inhibition, converting enzyme inhibition, and angiotensin II antagonism in rats." Cardiovasc. Pharmacol (1990) 16\(Suppl. 4):560–564.
   Google Scholar
• GLASSMAN HN, KLEINERT HD, BOGER RS et al: Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor. .1. Cardiovasc. Pharmacol (1990) 16\(Supp1.4):S76–S81.
   Google Scholar
• AZIZI M, GUYENE TT, CHATELLIER G et al.: Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension. Hypertens. (1994) 12(0419–427.
   Web of Science ®Google Scholar
• BOGER RS, GLASSMAN HN, CAVANAUGH JH et al: Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension. Hypertension (1990) 15(6 Pt 2):835–840.
   Google Scholar
• HIMMELMANN A, BERGBRANT A, SVENSSON A et al: Remikiren(Ro 42-5892)-an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system. Am. J. Hypertens. (1996) 9(6):517–522.
   Google Scholar
• RONGEN GA, LENDERS JW, KLEINBLOESEM CH et al.: Efficacy and tolerability of the renin inhibitor Ro 42-5892 in patients with hypertension. Clin. Pharmacol Ther. (1993) 54(5):567–577.
   PubMed Web of Science ®Google Scholar
• VAN DEN MEIRACKER AH, ADMIRAAL PJ, DERKX FH et al: Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension. Hypertens. (1993) 11(8):831–838.
   Web of Science ®Google Scholar
• NEISIUS D, WOOD JM, HOFBAUER KG: Renal vasodilatation after inhibition of renin or converting enzyme in marmoset. Am. .1. Physiol (1986)251(5 Pt 2):H897–H902.
   Google Scholar
• VERBURG KM, KADAM JR, YOUNG GA et al.: Effect of intrarenal renin inhibition on renal hemodynamics and excretory function. Am. J. Physiol (1990) 259(1 Pt 2):R7–R14.
   Google Scholar
• EL AMRANI Al, MENARD J, GONZALES MF et al.: Effects of blocking the angiotensin II receptor, converting enzyme, and renin activity on the renal hemodynamics of normotensive guinea pigs. .1. Cardiovasc. Pharmacol (1993) 22(2):231–239.
   Google Scholar
• CLOZEL JP, VENIANT MM, QIU C et al: Renal vascular and biochemical responses to systemic renin inhibition in dogs at low renal perfusion pressure. Cardiovasc. Pharmacol (1999) 34(5):674–682.
   PubMed Web of Science ®Google Scholar
• FISHER ND, ALLAN D, KIFOR I et al: Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans. Hypertension (1994) 23(1):44–51.
   Google Scholar
• VAN PAASSEN P, DE ZEEUW D, NAVIS G et al.: Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol Dial. Transplant. (2000) 15(5):637–643.
   PubMed Web of Science ®Google Scholar
• RICHTER WE WHITBY BR, CHOU RC: Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals. Xenobiotica (1996) 26(3):243–254.
   PubMed Web of Science ®Google Scholar
• SWEET CS, LUDDEN CT, FREDERICK CM et al: Comparative hemodynamic effects of MK-422, a converting enzyme inhibitor, and a renin inhibitor in dogs with acute left ventricular failure. Cardiovasc. Pharmacol (1984) 6(6):1067–1075.
   PubMed Web of Science ®Google Scholar
• MENTO PF, MAITA ME, MURPHY WR et al.: Comparison of angiotensin-converting enzyme and renin inhibition in rats following myocardial infarction. Cardiovasc. Pharmacol (1993) 21(5):791–796.
   PubMed Web of Science ®Google Scholar
• FITZPATRICK MA, RADEMAKER MT, CHARLES CJ et al.: Comparison of the effect of renin inhibition and angiotensin-converting enzyme inhibition in ovine heart failure. Cardiovasc. Pharmacol (1992) 19(2):169–175.
   PubMed Web of Science ®Google Scholar
• ZHANG Q, KOHARA K, QUI HY et al: Comparative effects of three sites of renin-angiotensin blockade on the regression of left ventricular hypertrophy in spontaneously hypertensive rats. Am. Ther. (1997) 4(5-6):199–202.
   PubMedGoogle Scholar
• NEUBERG GW, KUKIN ML, PENN J et al.: Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure. Am. Cardiol (1991) 67(1):63–66.
   PubMed Web of Science ®Google Scholar
• KIOWSKI W, BEERMANN J, RICKENBACHER P et al: Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition. Circulation (1994) 90(6):2748–2756.
   Google Scholar
• VIEIRA E, BINGGELI A, BREU V et al.: Substituted piperidines-highly potent renin inhibitors due to induced fit adaptation of the active site. Bioorg. Med. Chem. Lett. (1999) 9(10):1397–1402.
   PubMed Web of Science ®Google Scholar
• OEFNER C, BINGGELI A, BREU Vet al.: Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases? Chem. Biol. (1999) 6(3):127–131.
   Google Scholar
• BURSAVICH MG, RICH DH: Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. Med. Chem. (2002) 45(3):541–558.
   Web of Science ®Google Scholar
• GULLER R, BINGGELI A, BREU Vet al.: Piperidine-renin inhibitors compounds with improved physicochemical properties. Bioorg. Med. Chem. Lett (1999) 9(10):1403–1408.
   Google Scholar
• MARKI HP, BINGGELI A, BITTNER B et al: Piperidine renin inhibitors: from leads to drug candidates. Farmaco (2001) 56(1-2):21–27.
   PubMedGoogle Scholar
• ••First detailed disclosure of the discovery ofnovel non-peptide peptidomirnetic renin inhibitors based on the piperidine scaffold and demonstration by X-ray crystallography of a novel flap-opened renin inhibitor binding conformation.
   Google Scholar
• MULLER DN, DECHEND R, MERVAALA EM et al.: NF-icB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension (2000) 35(1Pt 2):193–201.
   Google Scholar
• RAHUEL J, RASETTI V, MAIBAUM J et al.: Structure-based drug design: the discovery of novel non-peptide orally active inhibitors of human renin. Chem. Biol. (2000) 7(7):493–504.
   PubMedGoogle Scholar
• ••Detailed outline of the design and discoveryof a novel class of non-peptide renin inhibitors leading to the clinical development compound aliskiren.
   Google Scholar
• MAIBAUM J, STUTZ S, GOSCHKE R et al.: Structural modification of the P2' position of 2,7-dialkyl substituted 5(.9-amino-4 (5)-hydroxy-8-phenyl-octanecarboxamides: discovery of a potent non-peptide human renin inhibitor active after once daily dosing in marmosets. XVth EFMC Int. Symp. Med. Chem. Abstract book. Edinburgh, UK (6–10 Sept 1998):230.
   Google Scholar
• MEALY NE, CASTANERJ, SILVESTRE J: Aliskiren Fumarate. Drugs of the Future (2001) 26:1139–1148.
   Google Scholar
• DONDONI A, DE LATHAUWER G, PERRONE D: A convergent synthesis of the renin inhibitor SPP-100 using a nitrone intermediate. Tetrahedron Letters (2001) 42:4819–4823.
   Web of Science ®Google Scholar
• HEROLD P, DUTHALER R, RIHS G et al.: A versatile and stereocontrolled synthesis of hydroxyethylene dipeptide isosteres. I. Org. Chem. (1989) 54(5):1178–1185.
   Web of Science ®Google Scholar
• ALLIKMETS K: Aliskiren (Speedel). CLIFF. Opin. Investig. Drugs (2002) 3(10):1479–1482.
   PubMedGoogle Scholar
• NUSSBERGERJ, WUERZNER G, JENSEN C et al.: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension (2002) 39(1):E1–E8.
   Web of Science ®Google Scholar
• ••The first study to demonstrate effectiverenin inhibition by oral administration of aliskiren in humans.
   Google Scholar
• O'BRIEN E, STANTON A, BARTON J et al.: Dose-response antihypertensive efficacy of Aliskiren (SPP 100), an orally active renin inhibitor. Am. .1. Hypertens. (2002) 15(4 Supp1.1):A56–A57.
   Google Scholar
• •Recent abstract describing the blood pressure lowering effects of oral doses of aliskiren in hypertensive patients.
   Google Scholar
• SCHULZ DW, MANSBACH RS, SPROUSE J et al: CP-154,526: a potent and selective non-peptide antagonist of corticotropin releasing factor receptors. Proc. Natl. Acad. Sci. USA (1996) 93(19):10477–10482.
   PubMed Web of Science ®Google Scholar
• PALS DT, DEGRAAF GL, COUCH SJ et al.: Additive combination studies of captopril and ditekiren, a renin inhibitor, in non-human primates. Clin. Exp. Hypertens. A (1991) 13(3):425–436.
   PubMed Web of Science ®Google Scholar
• FOSSA AA, WEINBERG LJ, BARBER RLet al.: Synergistic effect on reduction in blood pressure with coadministration of the renin inhibitor, CP-80,794, and the angiotensin converting enzyme inhibitor, captopril. Cardiovasc. Phannacol (1992) 20(1):75–82.
   Google Scholar
• BITTNER B, CHOU R, SCHLEIMER M et al.: Preformulation approaches to improve the oral bioavailability of two novel piperidine renin inhibitors in dog. Arznelinittelforschung (2002) 52(8):593–599. Patents
   Google Scholar